The study drug, RBX2660, is approved by the US Food and Drug Administration (FDA), and marketed in the United States as REBYOTA™ (fecal microbiota, live – jslm) 1 for rectal administration only. Study doctors want to find out if RBX2660 is also effective in preventing CDI recurrence when given by colonoscopy.